Problem of replacement hormonal therapy from the point of view of evidence-based medicine


Cite item

Full Text

Abstract

Till now there is uncertainty concerning of benefits and risk of the hormone replacement therapy (HRT) in menopause regarding its effects on the cardiovascular system, breast, thromboembolic complications, cognitive disturbances and Alzheimer disease. If the women's quality of life is not decreased and menopause can be considered physiological, the risk of HRT is not approving its using. But in the same time, if the menopause symptoms exist, HRT is the only and effective way of its reduction, improving of quality of life and sexuality. There are no other therapies which can be compared with HRT. The article includes the recommendations of the Executive committee of the International associations of menopause of HRT using during menopause, developed on the basis of results of metaanalysis of many trials.

References

  1. Медицина климактерия / Под ред. В.П. Сметник. Ярославль, 2006. 848 с.
  2. Подзолкова Н.М., Подзолков В.И., Можарова Л.Г. и др. Гормональный континуум женского здоровья: эволюция сердечно-сосудистого риска от менархе до менопаузы // Сердце. 2004. Т. 3. № 6. С. 276-279.
  3. Anderson B, Mattsson LA, Hahn L, et al. Hormone replacement therapy decreases hyperandrogenia and improves homeostasis of glucose and lipid profile in insulin independent diabetes militus women at postmenopause. J Clin Endocrinol Metab 1997;82(2):638-43.
  4. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.
  5. Brussaard HE, Geversen Leuven LA, Kluft C. Effect of 17-beta estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Ateroscler Thromb Vase Biol 1997;17(2):324-30.
  6. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-45.
  7. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53.
  8. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-32.
  9. Fedele L, Bianchi S, Raffaelli R, et al. Comparison of transdermal estradiol and tibolon for the treatment of oophorectomised women with deep residual endometriosis. Maturitas 1999;32(3):189-93.
  10. Godsland IF, et al. Insulin resistence, secretion and elimination in postmenopausal women receiving transdermal hormone replacement therapy. Metabolism 1993;42:846-53.
  11. Herkert O, et al. Gestadene und das Glucocorticoid Dexamethason erhohen die Trombin-Receptor Expression in kultivierten glatten GefeKmuskelzellen. Geburtch Frauenheilk 2000;60:78.
  12. Herrington DM, Reboussin DM, Broshihan KB, et al. Effect of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343(8):522-29.
  13. Hodis HN, Mack WJ, Azen SP, et al for the Womens Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349(6):535-45.
  14. Huang AJ, Ettinger B, Vitinghoff E, et al. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol on bone turnover and BMD in postmenopausal women. J Bone Min Res 2007;22:1791-97.
  15. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-21.
  16. Kim CJ, Jang HC, Cho DH, et al. Effect of Hormone replacement therapy on lipoprotein (A) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81.
  17. Lindsay R, Tohme JF. Estrogen treatment of patient with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-95.
  18. Lobo R. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004;164:482-84.
  19. Lundstrom E, Bygdeson M, Svane G, et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic density. Climacteric 2007;10:249-56.
  20. Miya Y, Sumino H, Ichikawa S, et al. Effects of Hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hypertens Res 2002;25(2):153-59.
  21. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602.
  22. McCarty MF. Androgenic progestegens amplify the breast cancer risk associated with Hormone replacement therapy by boosting IGF-I activity. Med Hypotesis 2001;56:213-16.
  23. Palmer JR, Rosenberg L, Shapiro S. Reproductive factors and risk of myocardial infarction. Am J Epid 1992;136:408-16.
  24. Parker M, Bosscher J, Barnhill D. Obstet Gynecol 1993;82(2):187-90.
  25. Pansini F, Bonaccorsi G, Calisesi M. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas 1993;17:181-90.
  26. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
  27. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
  28. Santen RJ, Boyd NF, Chlebowski RT, et al. Breast Cancer Prevention Collaborative Group. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169-87.
  29. Seely EW, et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999;33:1190-94.
  30. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57.
  31. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer's disease on older women the Cache County study. JAMA 2002;288:2123-29.
  32. Nilas L, Loft A. Ugeskr Laeger 1993;155(47):3818-22.
  33. Meyer PM, Powell LH, Wilson RS, et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 2003;61:801-06.
  34. Maki PM, Drogos LL, Rubin LH, et al. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause 2008;in press.
  35. Woods NF, Smith-Dijulio K, Percival DB, et al. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study. J Womens Health 2007;16:667-77.
  36. Espeland MA, Rapp SR, Shumaker SA, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA 2004;291:2959-68.
  37. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2306&mid=1085056570&magid=173

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies